*
Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree NA=Not applicable to my practice
54321NA
The information and/or skills learned will enhance my professional competence or ability.
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.
*
Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree NA=Not applicable to my practice
54321NA
Recognize the role of molecular histopathology in the diagnosis and characterization of primary brain tumors.
Identify the strengths and limitations of advanced imaging in the diagnosis and post-treatment follow-up of patients with primary brain tumors.
Evaluate current contemporary management of primary brain tumors incorporating advances in systemic therapy, tumor neurosurgery and radiation therapy.
Examine systemic therapy, neurological and radiotherapeutic breakthroughs, which influence management of patients with CNS malignancies.
Apply a comprehensive patient management approach to brain metastasis.
Evaluate the roles of radiation therapy, targeted therapy, immunotherapy and neurosurgery.
Examine breakthroughs in the use of biomarkers and molecular profiling of CNS tumors.
*
Scoring key: 5=Very effective, 4= Effective, 3= Somewhat effective, 2= Slightly effective, 1= Completely Ineffective, NA=Not Applicable Speakers are listed according to the lecture schedule.
54321NA
Molecular Histopathology is the Standard - Charles G. Eberhart, M.D., Ph.D.
Advanced Tumor Imaging: Strengths and Limitations - Kevin Abrams, M.D.
Tumor Neurosurgery in the Modern Era - Vitaly Siomin, M.D.
Systemic Therapy: What We Know - Yazmin Odia, M.D.
Radiation Therapy: How We Got Here - Arjun Sahgal, M.D.
Targeted Therapy Update - Ingo Mellinghoff, M.D.
Immuno-therapy Breakthroughs - Mark Gilbert, M.D.
Next Generation Radiation Therapy - Arjun Sahgal, M.D.
Tumor Neurosurgical Advances - Guy McKhann, M.D.
Immunotherapy Breakthroughs for Metastases - Veronica Chiang, M.D.
Immunotherapy and Targeted Therapy in Brain Metastases: Emerging Options in Precision Medicine - Priscilla Brastianos, M.D.
The Role of Multi-Institutional Collaboration in Neurooncology - Ricardo Komotar, M.D.
Molecular Profiling of Metastases - Priscilla Brastianos, M.D.
Molecular Basis of Leptomeningeal Metastases - Adrienne Boire, M.D.
BOLD fMRI as a Glioma Biomarker - Jack Grinband, M.D.
Maximizing Surgical Outcome in Low-grade Glioma - Hugues Duffau, M.D.
Radiation Therapy: Where Do We Go From Here - Ranjit Bindra, M.D.
*
*
*
*
*
*
*
*
*
*
*
*
*